Eva Schaefer-Jansen: Good morning, good afternoon and good evening to everyone. Thank you for joining us to review Sanofi s Second Quarter 2023 Results followed by Q&A session.
Nuria Pascual: Hello everyone, and welcome to the Grifols Second Quarter 2023 Conference Call. Thank you very much for taking the time to join us today.
Investors could be forgiven if talk of a potential suicide risk associated with a new class of diabetes and weight loss drugs led to skittishness last week.
The hit Wegovy weight-loss drug is on track for sales of over $4 billion this year in the U.S. alone, despite its manufacturer Novo Nordisk struggling to.